Logo image of SBFM

SUNSHINE BIOPHARMA INC (SBFM) Stock Fundamental Analysis

NASDAQ:SBFM - US8677817004 - Common Stock

1.5 USD
+0.02 (+1.35%)
Last: 8/28/2025, 3:37:36 PM
Fundamental Rating

4

SBFM gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 547 industry peers in the Biotechnology industry. SBFM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SBFM shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SBFM has reported negative net income.
In the past year SBFM has reported a negative cash flow from operations.
In the past 5 years SBFM always reported negative net income.
SBFM had a negative operating cash flow in each of the past 5 years.
SBFM Yearly Net Income VS EBIT VS OCF VS FCFSBFM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -19.73%, SBFM is in the better half of the industry, outperforming 77.33% of the companies in the same industry.
SBFM has a Return On Equity of -24.55%. This is amongst the best in the industry. SBFM outperforms 81.35% of its industry peers.
Industry RankSector Rank
ROA -19.73%
ROE -24.55%
ROIC N/A
ROA(3y)-41.58%
ROA(5y)-191.13%
ROE(3y)-55.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SBFM Yearly ROA, ROE, ROICSBFM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K 4K -4K 6K

1.3 Margins

The Gross Margin of SBFM (33.33%) is better than 74.04% of its industry peers.
In the last couple of years the Gross Margin of SBFM has declined.
The Profit Margin and Operating Margin are not available for SBFM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.34%
GM growth 5Y-8.47%
SBFM Yearly Profit, Operating, Gross MarginsSBFM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

SBFM does not have a ROIC to compare to the WACC, probably because it is not profitable.
SBFM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SBFM has more shares outstanding
There is no outstanding debt for SBFM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SBFM Yearly Shares OutstandingSBFM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
SBFM Yearly Total Debt VS Total AssetsSBFM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -1.10, we must say that SBFM is in the distress zone and has some risk of bankruptcy.
SBFM's Altman-Z score of -1.10 is in line compared to the rest of the industry. SBFM outperforms 57.77% of its industry peers.
SBFM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.1
ROIC/WACCN/A
WACC9.72%
SBFM Yearly LT Debt VS Equity VS FCFSBFM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

SBFM has a Current Ratio of 5.00. This indicates that SBFM is financially healthy and has no problem in meeting its short term obligations.
SBFM's Current ratio of 5.00 is in line compared to the rest of the industry. SBFM outperforms 54.48% of its industry peers.
SBFM has a Quick Ratio of 2.66. This indicates that SBFM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.66, SBFM is doing worse than 65.45% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5
Quick Ratio 2.66
SBFM Yearly Current Assets VS Current LiabilitesSBFM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.92% over the past year.
SBFM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.22%.
The Revenue has been growing by 340.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)85.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.08%
Revenue 1Y (TTM)19.22%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%1.15%

3.2 Future

The Earnings Per Share is expected to grow by 41.48% on average over the next years. This is a very strong growth
Based on estimates for the next years, SBFM will show a very strong growth in Revenue. The Revenue will grow by 26.02% on average per year.
EPS Next Y98.88%
EPS Next 2Y41.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year19.64%
Revenue Next 2Y26.02%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SBFM Yearly Revenue VS EstimatesSBFM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
SBFM Yearly EPS VS EstimatesSBFM Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 0 -100 -200 -300

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

SBFM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
SBFM is valuated rather expensively with a Price/Forward Earnings ratio of 18.38.
Based on the Price/Forward Earnings ratio, SBFM is valued cheaply inside the industry as 93.97% of the companies are valued more expensively.
SBFM is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.80, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 18.38
SBFM Price Earnings VS Forward Price EarningsSBFM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SBFM Per share dataSBFM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40 -50

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SBFM's earnings are expected to grow with 41.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.48%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SBFM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SUNSHINE BIOPHARMA INC

NASDAQ:SBFM (8/28/2025, 3:37:36 PM)

1.5

+0.02 (+1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-03 2025-11-03
Inst Owners1.74%
Inst Owner Change127%
Ins Owners0.05%
Ins Owner Change0%
Market Cap6.84M
Analysts82.86
Price Target7.14 (376%)
Short Float %6.7%
Short Ratio2.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-97.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-177.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-54.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 18.38
P/S 0.19
P/FCF N/A
P/OCF N/A
P/B 0.27
P/tB 0.29
EV/EBITDA N/A
EPS(TTM)-51.88
EYN/A
EPS(NY)0.08
Fwd EY5.44%
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS7.97
BVpS5.63
TBVpS5.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.73%
ROE -24.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.33%
FCFM N/A
ROA(3y)-41.58%
ROA(5y)-191.13%
ROE(3y)-55.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.34%
GM growth 5Y-8.47%
F-Score4
Asset Turnover1.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 549.76%
Cap/Sales 4.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5
Quick Ratio 2.66
Altman-Z -1.1
F-Score4
WACC9.72%
ROIC/WACCN/A
Cap/Depr(3y)874.71%
Cap/Depr(5y)526.53%
Cap/Sales(3y)5.32%
Cap/Sales(5y)3.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.08%
EPS Next Y98.88%
EPS Next 2Y41.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)19.22%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%1.15%
Revenue Next Year19.64%
Revenue Next 2Y26.02%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y5.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.81%
OCF growth 3YN/A
OCF growth 5YN/A